Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Clinical Trials01:16

Clinical Trials

10.4K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
10.4K
Clinical Trials: Overview01:11

Clinical Trials: Overview

4.9K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.9K
Statistical Software for Data Analysis and Clinical Trials01:12

Statistical Software for Data Analysis and Clinical Trials

1.5K
Statistical software is pivotal in data analysis and clinical trials by providing tools to analyze data, draw conclusions, and make predictions. These software packages range from simple data management applications to complex analytical platforms, supporting various statistical tests, models, and simulation techniques. Their significance lies in their ability to handle vast amounts of data with precision and efficiency, enabling researchers to validate hypotheses, identify trends, and make...
1.5K
Trial and Error and Algorithm01:12

Trial and Error and Algorithm

407
A problem-solving strategy is a plan of action used to find a solution. Different strategies have distinct action plans. Trial and error involves trying different solutions until one works. For instance, to fix a broken printer, you might check ink levels, ensure the paper tray isn't jammed, and verify the printer's connection to your laptop. This method can be time-consuming but is commonly used. Thomas Edison, for example, used trial and error to find a suitable filament for the light...
407
Group Design02:01

Group Design

10.4K
The most basic experimental design involves two groups: the experimental group and the control group. The two groups are designed to be the same except for one difference— experimental manipulation. The experimental group gets the experimental manipulation—that is, the treatment or variable being tested—and the control group does not. Since experimental manipulation is the only difference between the experimental and control groups, we can be sure that any differences between...
10.4K
Factorial Design02:01

Factorial Design

13.8K
Factorial Analysis is an experimental design that applies Analysis of Variance (ANOVA) statistical procedures to examine a change in a dependent variable due to more than one independent variable, also known as factors. Changes in worker productivity can be reasoned, for example, to be influenced by salary and other conditions, such as skill level. One way to test this hypothesis is by categorizing salary into three levels (low, moderate, and high) and skills sets into two levels (entry level...
13.8K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Efficacy, pharmacokinetic and pharmacodynamic evaluation of apaziquone in the treatment of non-muscle invasive bladder cancer.

Expert opinion on drug metabolism & toxicology·2017
Same author

Access to innovative oncology medicines in Europe.

Annals of oncology : official journal of the European Society for Medical Oncology·2015
Same author

Present and future breast cancer management--bench to bedside and back: a positioning paper of academia, regulatory authorities and pharmaceutical industry.

Annals of oncology : official journal of the European Society for Medical Oncology·2013
Same author

Actual developments in European regulatory and health technology assessment of new cancer drugs: what does this mean for oncology in Europe?

Annals of oncology : official journal of the European Society for Medical Oncology·2013
Same author

Serum CD44 levels predict survival in patients with low-risk myelodysplastic syndromes.

Critical reviews in oncology/hematology·2010
Same author

Investigator-initiated trials of targeted oncology agents: why independent research is at risk?

Annals of oncology : official journal of the European Society for Medical Oncology·2010

Related Experiment Video

Updated: Jan 30, 2026

In Silico Clinical Trials for Cardiovascular Disease
09:09

In Silico Clinical Trials for Cardiovascular Disease

Published on: May 27, 2022

2.3K

Innovation in oncology clinical trial design.

J Verweij1, H R Hendriks2, H Zwierzina3

  • 1Dept Medical Oncology, Erasmus University Medical Center, Rotterdam, the Netherlands.

Cancer Treatment Reviews
|January 22, 2019
PubMed
Summary

Cancer drug development is shifting towards targeted therapies for specific patient subgroups. Novel clinical trial designs and regulatory approaches are essential for efficient drug approval and patient access.

Keywords:
Drug developmentDrug regulationEstimand frameworkInnovative clinical trial designOncologyPrecision medicine

More Related Videos

Generation of Comprehensive Thoracic Oncology Database - Tool for Translational Research
11:18

Generation of Comprehensive Thoracic Oncology Database - Tool for Translational Research

Published on: January 22, 2011

16.5K
The Innovation Arena: A Method for Comparing Innovative Problem-Solving Across Groups
14:14

The Innovation Arena: A Method for Comparing Innovative Problem-Solving Across Groups

Published on: May 13, 2022

6.4K

Related Experiment Videos

Last Updated: Jan 30, 2026

In Silico Clinical Trials for Cardiovascular Disease
09:09

In Silico Clinical Trials for Cardiovascular Disease

Published on: May 27, 2022

2.3K
Generation of Comprehensive Thoracic Oncology Database - Tool for Translational Research
11:18

Generation of Comprehensive Thoracic Oncology Database - Tool for Translational Research

Published on: January 22, 2011

16.5K
The Innovation Arena: A Method for Comparing Innovative Problem-Solving Across Groups
14:14

The Innovation Arena: A Method for Comparing Innovative Problem-Solving Across Groups

Published on: May 13, 2022

6.4K

Area of Science:

  • Oncology
  • Clinical Pharmacology
  • Drug Development

Background:

  • Cancer drug development is evolving from broad histological classifications to targeted agents for molecularly defined subpopulations.
  • This paradigm shift necessitates innovative clinical trial designs and regulatory assessment tools.
  • The increasing complexity of targeted therapies, including combinations, demands enhanced operational efficiency and early decision-making strategies.

Purpose of the Study:

  • To describe innovative clinical trial designs for targeted cancer therapies.
  • To discuss the challenges and efforts of the pharmaceutical industry and regulatory authorities in adapting to these changes.
  • To emphasize the need for collaboration among stakeholders to advance novel oncology clinical trial design.

Main Methods:

  • Review and description of innovative clinical trial designs, including their advantages and disadvantages.
  • Analysis of the evolving landscape of cancer drug development and regulatory approval processes.
  • Discussion of strategies for early-stage decision-making and candidate drug selection.

Main Results:

  • Traditional randomized Phase III trials are often not feasible or ethical for small, molecularly defined cancer populations.
  • Alternative strategies, such as accelerated approval based on non-randomized Phase II trials, are being adopted.
  • Pharmaceutical companies and regulatory bodies are actively developing and implementing new approaches.

Conclusions:

  • The paradigm shift in cancer biology necessitates a re-evaluation of benefit-risk analyses for drug approval.
  • Innovative trial designs and adaptive regulatory pathways are crucial for bringing novel oncology agents to patients efficiently.
  • Continued collaboration and open discussion among all stakeholders are vital for progress in oncology clinical trial design.